Dermatologic toxicity is the most frequently reported irAE in patients who receive anti–PD-1/PD-L1 monotherapy (Villadolid and Amin, 2015; Kumar et al., 2017), and nearly one-third of patients experience dermatologic AEs including rash, pruritus, and vitiligo. This evidence concerns the gene RPL17 and vitiligo.